GlassScriptPhysician profile
Erum Sana Khalid
NPI 1043662323
$2,632.51
in general payments reported to CMS, 2019-2025
23 companies · $1,295 in 2025
The $1,295 reported for 2025 was more than what 90% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $13.57 · 2022: $266 · 2023: $575 · 2024: $483 · 2025: $1,295.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,353.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,353.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $469.47 | 2022-2025 | Mounjaro, Zepbound, Jardiance |
| Novo Nordisk INC | $394.13 | 2023-2025 | Wegovy, Ozempic, Rybelsus |
| Pfizer INC. | $318.15 | 2023-2025 | |
| Abbvie INC. | $222.75 | 2022-2025 | |
| Abbott Laboratories | $169.33 | 2023-2025 | Freestyle Libre 3 |
| Glaxosmithkline, LLC. | $144.83 | 2022-2025 | Shingrix, Bexsero, Arexvy |
| Supernus Pharmaceuticals, INC. | $142.68 | 2025 | Qelbree |
| Merck Sharp & Dohme LLC | $138.39 | 2022-2024 | Belsomra, Gardasil 9, Capvaxive |
| Janssen Pharmaceuticals, INC | $110.36 | 2023-2025 | Spravato |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $108.08 | 2022-2025 | Xifaxan, Trulance |
| Amgen INC. | $59.61 | 2023-2025 | Repatha, Otezla, Repatha |
| Exact Sciences Corporation | $52.63 | 2023 | Cologuard Collection Kit |
| Organon LLC | $44.29 | 2024-2025 | Nexplanon |
| Shield Therapeutics INC | $43.98 | 2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $37.70 | 2022-2025 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceutical Holding Company LTD. | $35.60 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $29.97 | 2025 | Airsupra, Breztri |
| Corium, LLC | $23.85 | 2025 | Azstarys |
| Ferring Pharmaceuticals INC. | $22.61 | 2023 | Rebyota |
| Dynavax Technologies Corporation | $20.24 | 2023 | Heplisav-B |
| Idorsia Pharmaceuticals US INC | $17.58 | 2023 | Quviviq |
| Genentech USA, INC. | $13.57 | 2021 | |
| Dexcom, INC. | $12.71 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Erum Khalid listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.